CLOs on the Move

Urban Health Plan

www.urbanhealthplan.org

 
Urban Health Plan is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Bronx, NY. To find more information about Urban Health Plan, please visit www.urbanhealthplan.org
  • Number of Employees: 0-25
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Viju Jacob
Assistant VP Medical Regulatory, Policy and External Affairs Profile

Similar Companies

MEDNET USA

MEDNET USA is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.

InnoTraction

InnoTraction is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Shared Health Svc

Shared Health Svc is a La Crosse, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stilla Technologies

Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla`s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the world`s first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics.